Drug Trial Radar · NCT04004429
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Aug 26, 2019
Primary completion
Nov 16, 2021
Study completion Nov 16, 2021
Sponsor
- Lead sponsor
- SynAct Pharma ApsIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) \> 22, who are to start up-titration with methotrexate.
Conditions
- Rheumatoid Arthritis
Interventions
50 mg AP1189Drug
50 mg AP1189 powder in bottle
AP1189Drug
100 mg AP1189 powder in bottle
PlaceboDrug
Placebo powder in bottle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Clinical Disease Activity Index (CDAI)Time frame: 4 weeks
- Change in Clinical Disease Activity Index (CDAI)Time frame: 4 weeks
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Aarhus Universitetshospital
Aarhus, Denmark
Diakonhjemmet Sykehus
Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.